Please login to the form below

Not currently logged in
Email:
Password:

everolimus

This page shows the latest everolimus news and features for those working in and with pharma, biotech and healthcare.

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

Pfizer and Arvinas announce $1bn deal for investigational oral protein degrader

Pfizer and Arvinas are also planning to initiate two additional trials of ARV-471 this year, including a second phase 1b combination trial with cancer growth blocker everolimus, as well as

Latest news

More from news
Approximately 8 fully matching, plus 68 partially matching documents found.

Latest from PMHub

  • Oncology drugs under AMNOG

    patients the comparator was a different targeted therapy, Afinitor (everolimus), rather than Nexavar - although for cytokine-pretreated patients the trial comparator could be used.The G-BA still exercises its right

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
McCann Health Medical Communications

We are the medical communications experts within McCann Health. Communicating science to bring meaning and positive change to people’s lives....

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....